Skip to Main Content

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

Conditions

Diseases of the Musculoskeletal System | Immune System

Phase III

What is the purpose of this trial?

The purpose of this study is to compare the effects, good or bad, of Obinutuzumab versus placebo on patients with lupus nephritis. Obinutuzumab is a monoclonal antibody that targets a type of white blood cells known as a B cell and is an approved drug for certain types of blood cancers. This study will help determine if using Obinutuzumab to reduce B cells will improve the signs and symptoms of lupus nephritis. If you meet the study requirements and are enrolled, you will be in this study for about 76 weeks.

  • Trial with
    Genentech, Inc.
  • Start Date
    09/14/2021
  • End Date
    10/06/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/22/2021
  • Study HIC
    #2000028219